0001209191-19-000242.txt : 20190102
0001209191-19-000242.hdr.sgml : 20190102
20190102161234
ACCESSION NUMBER: 0001209191-19-000242
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181228
FILED AS OF DATE: 20190102
DATE AS OF CHANGE: 20190102
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PAPADOPOULOS STELIOS
CENTRAL INDEX KEY: 0001202098
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35670
FILM NUMBER: 19501784
MAIL ADDRESS:
STREET 1: 3 SOMERSET DRIVE SOUTH
CITY: GREAT NECK
STATE: NY
ZIP: 11020
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Regulus Therapeutics Inc.
CENTRAL INDEX KEY: 0001505512
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 264738379
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10614 SCIENCE CENTER DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-202-6300
MAIL ADDRESS:
STREET 1: 10614 SCIENCE CENTER DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-12-28
0
0001505512
Regulus Therapeutics Inc.
RGLS
0001202098
PAPADOPOULOS STELIOS
C/O REGULUS THERAPEUTICS INC.
10614 SCIENCE CENTER DRIVE
SAN DIEGO
CA
92121
1
0
0
0
Common Stock
2018-12-28
4
P
0
50000
1.0914
A
835073
D
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.04 to $1.12 inclusive. The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
Christopher Aker, Attorney in Fact
2019-01-02